Rockefeller Capital Management
TRIB

Rockefeller Capital Management’s Trinity Biotech TRIB Stock Holding History

Rockefeller Capital Management’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-189
Closed -$1K – 4212
2022
Q3 		$1K Hold
189
– – ﹤0.01% 3794
2022
Q2 		$1K Hold
189
– – ﹤0.01% 4022
2022
Q1 		$1K Hold
189
– – ﹤0.01% 3787
2021
Q4 		$1K Hold
189
– – ﹤0.01% 3696
2021
Q3 		$2K Hold
189
– – ﹤0.01% 3485
2021
Q2 		$2K Buy
+189
New +$3.14K ﹤0.01% 3276

Other funds holding TRIB

HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return
SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
AC
Aristides Capital Louisville, Kentucky $462M AUM 28.94% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
WP
WealthSource Partners San Luis Obispo, California $1.54B AUM 16.68% 1-Year Est. Return

Rockefeller Capital Management's TRIB Position: Q4 2022 in Review

Rockefeller Capital Management sold out of Trinity Biotech (TRIB) in Q4 2022, closing a stake of 189 shares — an estimated $1K sold.

Rockefeller Capital Management first reported a position in TRIB in Q2 2021 and held it in 6 quarters. The position peaked at $2K in Q3 2021. 20 funds tracked by Wall St. Rank hold TRIB as of Q4 2022.

  • Rockefeller Capital Management reported no remaining Trinity Biotech position as of Q4 2022 after selling out during the quarter.
  • Rockefeller Capital Management sold 189 Trinity Biotech shares in Q4 2022, an estimated $1K.
  • Rockefeller Capital Management first reported a position in Trinity Biotech in Q2 2021 and held it in 6 quarters.
  • Rockefeller Capital Management's Trinity Biotech position peaked at $2K in Q3 2021.
  • 20 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2022.

Based on Rockefeller Capital Management's 13F filing for Q4 2022, filed 6 Mar 2023.